Loading clinical trials...

Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients | Clinical Trials | Clareo Health

COMPLETEDNA

Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients

Capnographic Monitoring Decrease the Incidence of Hypoxia of the Elderly Patients Undergoing Gastrointestinal Endoscopy Procedure: a Randomized Multicenter Clinical Trial

NCT05030870•RenJi Hospital

View on ClinicalTrials.gov

Summary

Hypoxia is the most common adverse event in gastrointestinal endoscopes sedated with propofol and sufentanil, especially in elderly people. The aim of this randomized study was to determine whether intervention based on additional capnographic monitoring reduces the incidence of hypoxia in gastrointestinal endoscopes procedures for elderly patients.

Eligibility

Age

65 - 79 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•65 ≤ Age \<80
•patients undergoing gastrointestinal endoscopes
•patients signed informed consent form
•ASA classification I-II

Exclusion Criteria

•Coagulation disorders or a tendency of nose bleeding
•An episode/exacerbation of congestive heart failure (CHF) that requires a change in medication, diet or hospitalization from any cause in the last 6 months
•Severe aortic stenosis or mitral stenosis
•Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months
•Acute myocardial infarction in the last 6 months
•Acute arrhythmia (including any tachycardia - or bradycardia) with the fluid of hemodynamics instability
•Diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy)
•Pre-existing bradycardia (heart rate \< 50 / min), or hypoxia (SaO2\< 90 % )
•Need supplemental oxygen because of pre-existing diseases
•Emergency procedure or surgery
+3 more criteria

Locations (3)

Henan Provincial People's Hospital

Zhenzhou, Henan, China

Qilu Hospital of Shandong University

Qingdao, Shandong, China

Renji Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

September 1, 2021

Primary Completion Date

September 1, 2022

Completion Date

January 1, 2023

Last Updated

March 19, 2024

Enrollment

1,800

ACTUAL participants

Conditions

HypoxiaGastric CancerGastric PolypColon PolypColon CancerEsophageal Cancer

Interventions

Capnography monitoring

DEVICE

Standard monitoring

DEVICE

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Resilience and Equity in Aging, Cancer, and Health (REACH)

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.